News

FiercePharma25d
AstraZeneca, Pfizer rebuked over breaking UK drug marketing rules on LinkedIn use
The PMCPA has dug into the industry’s LinkedIn activities once again. AstraZeneca received the harshest censure in the latest set of cases, taking a telling-off over one of its own posts ...
scmp.com25d
After China probe, is AstraZeneca’s new US$2.5 billion plan a blueprint for foreign firms?
Biopharmaceutical multinational AstraZeneca is not letting a bumpy 2024 dictate its path forward in China, and in the wake of a recent controversy emerges a multibillion-dollar commitment to China ...
FiercePharma1mon
AstraZeneca offers early look at Datroway-Tagrisso combo in EGFR lung cancer as phase 3 trial rolls on
As AstraZeneca awaits an FDA decision for its Daiichi Sankyo-partnered Datroway in EGFR-mutated non-small cell lung cancer (NSCLC), the British pharma has rolled out early data from a trial ...
Gebärmutterkrebs: Erhöhtes Risiko vor allem bei Frauen nach der Menopause
Hamburg (ots) - Mehr als drei Viertel (77 Prozent) der Frauen über 50 Jahre in Deutschland kennen den Risikofaktor höheres ...
Business Insider18d
AstraZeneca (AZN) Receives a Buy from UBS
In a report released today, Matthew Weston from UBS maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target of £142.00. The company’s shares opened today at p11 ...
FierceBiotech1mon
AstraZeneca's $800M rare disease bet hits primary phase 3 goal, but competitive strength still unclear
A phase 3 trial of AstraZeneca’s $800 million rare disease candidate has met its primary endpoint. The update keeps eneboparatide on track to come to market, but the lack of numbers in the ...
PresseBox29d
AstraZeneca und Mindpeak verkünden Zusammenarbeit und internationale Studie zum Einsatz KI-gestützter Brustkrebsdiagnostik
Mindpeak, ein führender Anbieter von KI-gestützten Lösungen für die digitale Pathologie, gibt eine neue Partnerschaft mit dem weltweit agierenden biopharmazeutischen Unternehmen AstraZeneca ...
Business Insider12d
AstraZeneca (AZN) Gets a Hold from Deutsche Bank
Deutsche Bank analyst Emmanuel Papadakis maintained a Hold rating on AstraZeneca (AZN – Research Report) today and set a price target of £110.00. The company’s shares opened today at p10,500. ...
Benzinga.com1mon
Eventful Monday For AstraZeneca - What's Going On?
Eneboparatide hits primary endpoint in AstraZeneca’s Phase 3 trial for chronic hypoparathyroidism, showing significant efficacy at 24 weeks. The EU approved AstraZeneca’s Imfinzi for limited ...
Nasdaq1mon
AstraZeneca To Buy Belgium's Cell Therapy Firm EsoBiotec In Up To $1 Bln Deal
(RTTNews) - British drug major AstraZeneca Plc (AZN, AZN.L) announced Monday that it has entered into a definitive agreement to acquire EsoBiotec, a biotechnology company, for a total ...
Na Presseportal9mon
Warum Vorsorge wichtig ist: Nierenscreenings bei Risikogruppen können Leben retten und Kosten senken - Presseportal
Herz-Kreislauf-, Nieren- und Stoffwechselerkrankungen (Cardiovascular, Renal and Metabolism, CVRM), stellen für AstraZeneca einen zentralen Therapiebereich dar. Das Unternehmen investiert in die ...